Highlights from the post:
PRQR has been the subject of a number of analyst reports. Zacks Investment Research downgraded shares of ProQR Therapeutics NV from a “buy” rating to a “hold” rating in a research report on Tuesday, January 17th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of ProQR Therapeutics NV in a research report on Wednesday, March 1st.Several hedge funds have recently made changes to their positions in PRQR. Baker BROS. Advisors LP bought a new stake in shares of ProQR Therapeutics NV during the third quarter valued at approximately $5,739,000. Redmile Group LLC increased its stake in shares of ProQR Therapeutics NV by 5.2% in the second quarter. Redmile Group LLC now owns 581,638 shares of the biopharmaceutical company’s stock valued at $2,815,000 after buying an additional 28,925 shares during the last quarter. Finally, Altrinsic Global Advisors LLC increased its stake in shares of ProQR Therapeutics NV by 2.7% in the third quarter. Altrinsic Global Advisors LLC now owns 210,556 shares of the biopharmaceutical company’s stock valued at $1,404,000 after buying an additional 5,556 shares during the last quarter. 37.10% of the stock is owned by institutional investors and hedge funds.
Shares of ProQR Therapeutics NV (NASDAQ:PRQR) remained flat at $4.80 during trading on Monday. The company had a trading volume of 96,430 shares. ProQR Therapeutics NV has a 12-month low of $3.55 and a 12-month high of $8.70. The company has a 50 day moving average price of $4.47 and a 200-day moving average price of $4.94. The stock’s market cap is $112.06 million.